Introduction
Despite suppression of HIV RNA in the plasma compartment with effective antiretroviral therapy, cerebrospinal fluid HIV RNA escape is reported [1, 2] . Rates of cerebrospinal fluid HIV RNA vary, with mean reported prevalence rates of 10% in neurologically asymptomatic subjects [3] [4] [5] [6] [7] [8] [9] [10] and 14% in neurologically symptomatic subjects undergoing cerebrospinal fluid examination for clinical reasons [11] [12] [13] [14] [15] [16] [17] [18] [19] . Recent case series describing rates of cerebrospinal fluid HIV RNA escape are summarized in Table S1 .
We previously reported cerebrospinal fluid HIV RNA escape in 21% of neurologically symptomatic persons living with HIV (PLWH) undergoing lumbar puncture examination between 2008 and 2010 [3] . Since our report and many of these case series, several characteristics of PLWH and therapies for PLWH have changed. First, antiretroviral therapies have changed notably with the introduction of the HIV strand transfer integrase inhibitors [20] . High rates of virological suppression are observed with integrase inhibitor-containing antiretroviral regimens and the majority of case series reporting rates of cerebrospinal fluid HIV RNA escape have not included substantial numbers of subjects receiving this class of drug. Secondly, the age of PLWH attending for clinical care has increased substantially over the past decade. Older individuals with HIV infection are reported to have high rates of noninfectious comorbidities such as Clinical details captured included age, gender, plasma HIV RNA, current and nadir CD4 lymphocyte counts, history of previously treated syphilis and full antiretroviral treatment history (including any history of antiretroviral drug resistance). Indications for cerebrospinal fluid examination included investigation for cognitive decline (n = 25), other central nervous system AIDS-defining illnesses (n = 3; cerebral toxoplasmosis, progressive multifocal leukoencephalopathy and cerebral candidiasis), neurosyphilis (n = 4) and central nervous system diseases not considered HIV-related (n = 6). The laboratory assay utilized to measure plasma and cerebrospinal fluid HIV RNA load was the Roche Cobas Ampliprep (Mannheim, Germany) assay with a lower limit of detection (LLQ) of < 20 HIV-1 RNA copies/mL with a 1-mL sample (n = 34). For small-volume samples (0.5-1 mL), the Roche Taqman 48 was used with an LLQ of < 38 copies/mL (n = 4).
All analyses were undertaken using SPSS statistics software version 24 (IBM Corporation, Armonk, NY). Cerebrospinal fluid HIV RNA escape was defined as a cerebrospinal fluid HIV RNA > 0.5 log 10 copies/mL greater than plasma HIV RNA where plasma HIV RNA was detectable, or detectable in cases where plasma HIV RNA was undetectable. Factors associated with a detectable cerebrospinal fluid HIV RNA were assessed using appropriate statistical tests in a univariate analysis.
Results
Subjects were predominantly male (n = 30; 79.9%) and had a median age of 51 years (Table 1) Plasma and/or cerebrospinal fluid HIV RNA was detectable in eight subjects (plasma detectable in seven and cerebrospinal fluid in six). In subjects with detectable cerebrospinal fluid HIV RNA, the median current CD4 cell count was 369.5 (IQR 235-655.5) cells/lL and the median nadir CD4 cell count was 135 (IQR 75-467) cells/lL, with both of these median CD4 counts being lower than those of the overall cohort. Two patients (5.3%) met the definition of cerebrospinal fluid HIV RNA escape. Both individuals were receiving antiretroviral therapy comprising tenofovir, emtricitabine and darunavir/ritonavir (800/100 mg once daily) and had a history of antiretroviral drug resistance. In a univariate analysis, two factors were statistically significantly associated with detectable cerebrospinal fluid HIV RNA; detectable plasma HIV RNA [odds ratio (OR) 75; 95% confidence interval CI: 5.68-990.14; P < 0.001] and documented presence of antiretroviral drug resistance mutations (OR 15; 95% CI: 1.75-128.39; P = 0.021). Weak associations observed with detectable cerebrospinal fluid HIV RNA included current CD4 cell count (P = 0.057), not currently receiving antiretroviral therapy (P = 0.059), antiretroviral therapy of < 6 months' duration (P = 0.063) and male gender (P = 0.094). No other factors were associated with detectable cerebrospinal fluid HIV RNA (P > 0.1 for all).
Discussion
In these HIV-positive individuals undergoing cerebrospinal fluid examination for clinical reasons since 2015, we observed cerebrospinal fluid HIV RNA escape in 5.3% of subjects. Our report adds to the body of literature reporting cerebrospinal fluid HIV RNA escape and reports a lower rate of cerebrospinal fluid escape compared with other recent reports.
The median age of our cohort was 51 years. Together with Eden et al.'s longitudinal study [13] , we report the oldest median age of PLWH in a cerebrospinal fluid escape case series. Given that PLWH are ageing, data on cerebrospinal fluid escape in such individuals are required. In general, high rates of compliance with antiretroviral therapy and high rates of virological suppression are reported in older PLWH, which may be associated with lower rates of detectable virus on cerebrospinal fluid examination [22] .
In our cohort, 17% of patients were receiving an integrase inhibitor-containing antiretroviral regimen, which is higher than the percentage in any other report to date. The high virological success rates, and relatively high inhibitory quotient of the cerebrospinal fluid concentration of the HIV integrase inhibitors [23, 24] , may also be an explanation for the lower rates of cerebrospinal fluid HIV RNA escape we have observed.
Several definitions of cerebrospinal fluid HIV RNA escape have been proposed, with nine definitions summarized in Table S1 . The definition of cerebrospinal fluid HIV RNA escape we utilized is that proposed in the Comorbidity Guidelines of the European AIDS Clinical Society (EACS) [25] . The lower rates of cerebrospinal fluid HIV RNA escape we report here are unlikely to be attributable to the definition we have used, given that this definition, which includes the presence of any detectable cerebrospinal fluid HIV RNA in cases where the plasma HIV RNA is undetectable, is more likely to classify some cases as escape compared with previous definitions which required cerebrospinal fluid HIV RNA to be elevated by specific quantities above plasma HIV RNA.
Our report has several limitations. Small numbers of individuals were included in our study and therefore we lack power to make observations that may be apparent in larger case series. In view of this, our analyses are limited to a univariate description. The phenotypes of the PLWH are reported; however, further details such as cognitive testing results, duration of known HIV seropositivity and details of other cerebrospinal fluid biomarkers are not available.
In summary, in this small case series of HIV-positive subjects undergoing lumbar puncture examination for clinical reasons, we have observed low rates of cerebrospinal fluid HIV RNA escape.
